Anne Webster
Family · Peoria, ILNPI 1124495379
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Abbott at 49.8% of the total. Among family clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 438 payments — averaging $125.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$27K
- Dexcom, Inc.$19K
- Medtronic$2K
- Insulet Corporation$2K
- Sanofi-aventis U.S. LLC$2K
- Novo Nordisk$489
- plus $2K from 21 others
What the payments were for
- Consulting fees$3,7007%
- Speaking & faculty fees$30,78656%
- Travel & lodging$10,98520%
- Food & beverage$8,98516%
- Education$3361%
- Other$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 207 | $27,315 |
| Dexcom, Inc. | 51 | $19,040 |
| Medtronic | 27 | $2,458 |
| Insulet Corporation | 14 | $1,986 |
| Sanofi-aventis U.S. LLC | 28 | $1,588 |
| Novo Nordisk | 11 | $489 |
| Amgen(2 entities) | 16 | $323 |
| AstraZeneca(2 entities) | 11 | $215 |
| Radius Health, Inc. | 10 | $193 |
| Xeris Pharmaceuticals, Inc. | 8 | $170 |
| Lilly USA, LLC | 9 | $164 |
| AbbVie | 8 | $148 |
| Tandem Diabetes Care, Inc. | 7 | $148 |
| Boehringer Ingelheim | 7 | $144 |
| Nestle Healthcare Nutrition Inc. | 5 | $81 |
| Novartis | 4 | $79 |
| Bayer | 3 | $71 |
| Amarin Pharma, Inc. | 2 | $39 |
| Mannkind Corporation | 2 | $33 |
| Corcept Therapeutics | 1 | $24 |
| BETA Bionics, Inc. | 1 | $24 |
| Amneal Pharmaceuticals LLC | 1 | $21 |
| Sequel Med Tech, LLC | 1 | $17 |
| Alvogen Inc | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Cequr Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$24,413
- DEXCOM G7 GSS (161)$18,207
- DEXCOM STELO GLUCOSE BIOSENSOR$2,706
- Omnipod$1,666
- INTELLIS ADAPTIVESTIM$808
- InPen$518
- MINIMED 780G$382
- SOLIQUA 100/33$103
- Wegovy$100
How this compares
$54,821 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,029 | $1,125,323 |
| MounjaroTirzepatide | 630 | $711,765 |
| JardianceEmpagliflozin | 799 | $648,260 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 179 | $260,208 |
| ForteoTeriparatide | 62 | $246,022 |
| TrulicityDulaglutide | 229 | $234,102 |
| Tresiba Flextouch U-100Insulin Degludec | 283 | $202,508 |
| JanuviaSitagliptin Phosphate | 181 | $127,506 |
| Humalog Kwikpen U-200Insulin Lispro | 57 | $127,301 |
| TradjentaLinagliptin | 177 | $98,407 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 639 | $98,210 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 92 | $97,522 |
| Novolog FlexpenInsulin Aspart | 300 | $83,183 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 187 | $82,802 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $78,585 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $164 | $1,211,893994 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $489 | $1,172,3111,152 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Synjardy Xr, Glyxambi | $144 | $876,6051,163 claims |
| AstraZenecaFarxiga | $215 | $69,437108 claims |
| Radius Health, Inc.Tymlos | $193 | $44,27217 claims |
| Alvogen IncTeriparatide | $13 | $43,43919 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,588 | $23,30131 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.
Other family in Peoria
- Ruth CarricoChicago$578K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
- Amy BrownellElk Grove Village$202K
- Brittony CroasdellChicago$192K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.